IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface. A recent Phase II trial revealed that felzartamab, an investigational ...
Verywell Health on MSN
7 types of treatments for IgA nephropathy
Medically reviewed by Jamin Brahmbhatt, MD IgA nephropathy (IgAN) is a kidney condition where antibodies (immune system ...
IgA nephropathy (IgAN), the most common primary glomerulonephritis worldwide, has an estimated incidence of 0.2-5 per 100,000 ...
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced positive topline full study results from the Phase 3 VISIONARY trial. VOYXACT® ...
Alternative pathway blockade via factor B inhibition limits C3 cleavage, amplification loop activity, and downstream membrane attack complex generation, addressing complement-mediated glomerular ...
Takeda ( TSE:4502/NYSE:TAK) today announced new interim data from the Phase 1b, open-label, proof-of-concept study of subcutaneous mezagitamab (TAK-079), an anti-CD38 monoclonal antibody with ...
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that VOYXACT ® (sibeprenlimab-szsi) preserved kidney function compared to ...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the first report describing the effects of lectin-pathway inhibition by narsoplimab on urinary complement levels in ...
OSAKA/CAMBRIDGE - Takeda (NYSE:TAK) announced that patients with IgA nephropathy treated with its investigational antibody mezagitamab maintained stable kidney function through 96 weeks, including 18 ...
− Takeda Initiated Pivotal Phase 3 Clinical Trials Evaluating Mezagitamab in Primary IgA Nephropathy and Immune Thrombocytopenia with Patient Enrollment Ongoing OSAKA, Japan & CAMBRIDGE, Mass., ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results